{
  "report_rows": [
    {
      "kpi": "USFS Local Case Volume Growth (%)",
      "prediction": "BEAT",
      "answer": "pred ~3.0% vs cons 2.65%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adj. EPS (Diluted, Operating)",
      "prediction": "IN-LINE",
      "answer": "pred ~$1.52 vs cons $1.5115",
      "confidence": "HIGH"
    },
    {
      "kpi": "Gross Margin (%)",
      "prediction": "IN-LINE",
      "answer": "pred ~18.85% vs cons 18.90%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Adj. EPS - FY2027 (initial)",
      "prediction": "UNCHANGED",
      "answer": "guide ~$4.925 vs cons $4.929",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Local Case Volume - Q1 FY2027 (directional)",
      "prediction": "BETTER",
      "answer": "guide 'at least 2.5%' vs cons ~2.17%",
      "confidence": "HIGH"
    },
    {
      "kpi": "Revenue - FY2027",
      "prediction": "UNCHANGED",
      "answer": "guide ~$88-90B vs cons $88.47B",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -2.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -2.5,
  "day5_path": "FADE",
  "day5_rationale": "FADE - no estimate revision catalyst; JRD overhang reasserts; volume beat already priced into the +14% idiosyncratic pre-print run",
  "day5_confidence": "MEDIUM"
}